Clinical profile of patients considered for biphasic insulin aspart 30:: baseline characteristics of insulin naive patients from the IMPROVE™ Study

被引：0

作者：

Kawamori, Ryuzo ^{[1
]}

Valensi, Paul ^{[2
]}

Orskov, Cathrine ^{[3
]}

Ligthelm, Robert J. ^{[4
]}

机构：

[1] Juntendo Univ, Sch Med, Tokyo 113, Japan

[2] Univ Paris 13, Jean Verdier Hosp, Dept Endocrinol Diabetol Nutr, Bondy, France

[3] Novo Nordisk AS, Copenhagen, Denmark

[4] EHM Clin, Rotterdam, Netherlands

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2008年 / 79卷

关键词：

D O I：

10.1016/S0168-8227(08)70804-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S65 / S66

页数：2

共 50 条

[21] Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
Onishi, Yukiko
Yamada, Kenichi
Zacho, Jeppe
Ekelund, Jan
Iwamoto, Yasuhiko
[J]. JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (02) : 210 - 217
[22] Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: Results from the Filipino cohort of the A1chieve study
Lim-Abrahan, Mary Anne
Yu-Gan, Susan
Jain, Anand B.
Sobrepena, Leorino M.
Racho, Veronica A.
[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2013, 100 : S35 - S40
[23] Clinical profile of patients moving from human premix to premix analogue insulin:: baseline characteristics of an IMPROVE™ study sub-group
Yang Wenying
Shaban, Joseph
Cumprecht, Janusz
Orskov, Cathrine
Valensi, Paul
[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 79 : S66 - S67
[24] Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) from the PREFER treat-to-target study
Liebl, Andreas
Prager, Rudolf
Kaiser, Marcel
Binz, Katharina
Gallwitz, Baptist
[J]. DIABETES, 2006, 55 : A460 - A461
[25] Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (lDet) and insulin aspart (IAsp) from the PREFER treat-to-target study
Liebl, A.
Compion, G.
Prager, R.
Binz, K.
Kaiser, M.
Gallwitz, B.
[J]. DIABETIC MEDICINE, 2007, 24 : 75 - 75
[26] Lower Insulin Needs in Asian vs Non-Asian Patients with Type 2 Diabetas Treated with Biphasic Insulin Aspart 30: Data from the IMPROVE Observational Study
Valensi, Paul
Yang, Wenying
Shah, Siddharth
Knudsen, Vibeke Kildegaard
[J]. DIABETES, 2009, 58 : A532 - A532
[27] The pharmacokinetic and pharmacodynamic properties of biphasic insulin aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin aspart 30 (BIAsp 30)
Bott, S
Tusek, C
Heinemann, L
Friberg, HH
Heise, T
[J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2005, 113 (09) : 545 - 550
[28] Improvement in Metabolic Control in Type 2 Diabetic Patients after Switching from Biphasic Human Insulin to Biphasic Insulin Aspart 30/70: An Observational Study in Hungary
Geroe, Laszlo
Gyimesi, Andras
Hidvegi, Tibor
[J]. DIABETES, 2009, 58 : A527 - A527
[29] Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix® 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study
Valensi, P.
Benroubi, M.
Borzi, V.
Gumprecht, J.
Kawamori, R.
Shaban, J.
Shah, S.
Shestakova, M.
Wenying, Y.
[J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (03) : 522 - 531
[30] Intensifying Insulin Therapy from Basal Insulin to Biphasic Insulin Aspart (BIAsp 30) Improves Glucose Control and Treatment Satisfaction in Patients with Type 2 Diabetes: South Korea Subgroup of IMPROVE™ Study
Kim, Chong Hwa
Jeong, Su Jin
Mok, Ji Oh
Ryu, Ohk Hyun
Lee, Kiyoung
Jeong, In Kyung
Lee, Byung Wan
Kim, Hyun Jin
Lee, Sora
Kim, Sun Woo
[J]. DIABETES, 2010, 59 : A566 - A566

← 1 2 3 4 5 →